Hinge Health: 56% Post-IPO Share Price growth increases confidence in the Digital Health Sector

Lloyd Price
1 day ago
17 min read

Executive Summary

(The information contained in this blog post is not intended to constitute and should not be construed as, investment advice.)

Hinge Health (NYSE: HNGE) has demonstrated a remarkable post-Initial Public Offering (IPO) performance, with its share price surging approximately 56% since its market debut in May 2025. This significant appreciation reflects robust investor confidence, driven by strong financial results and strategic advancements within the digital musculoskeletal (MSK) care market.

The company's first quarterly earnings report as a public entity for Q2 2025 showcased substantial revenue growth of 55% year-over-year, reaching $139.1 million, a figure that significantly exceeded analyst expectations. Despite reporting a notable GAAP net loss, primarily attributable to IPO-related stock-based compensation, Hinge Health achieved strong non-GAAP operating income and positive free cash flow, signalling operational efficiency and a clear trajectory toward sustained profitability.

Hinge Health's success is underpinned by its advanced AI-powered digital MSK platform. Following its IPO, the company strategically expanded its offerings with the introduction of HingeSelect, an in-person provider network, aiming to create a seamless, unified care experience. Strategic partnerships with major health plans and entities such as Amazon Health Services further solidify its market position and expand its reach to a broader user base.

While the company benefits from a rapidly expanding digital therapeutics market and strong demand for AI-enabled MSK solutions, it faces challenges including potential revenue concentration and uncertainties surrounding evolving digital health reimbursement policies. The ability to diversify revenue streams and adeptly navigate regulatory changes will be crucial for its sustained growth and long-term stability.

Hinge Health's successful IPO and strong initial performance serve as a positive indication for the broader digital health sector, potentially revitalising public market activity after a period of limited listings. Its integrated model, combining AI with in-person care, exemplifies a broader industry trend toward hybrid healthcare delivery and value-based care solutions.

Introduction: Hinge Health's Market Debut

Hinge Health, established in 2014, stands as a prominent digital musculoskeletal (MSK) care company. It provides an advanced AI-powered platform specifically designed to address and prevent joint and muscle pain, facilitate injury rehabilitation, and offer comprehensive post-surgical support. The company targets a substantial portion of the estimated $661 billion U.S. MSK healthcare expenditure. Its innovative approach leverages cutting-edge technology, including AI-powered motion tracking known as "TrueMotion" and wearable devices that deliver electrical nerve stimulation, all integrated with access to a network of expert clinicians. This combination allows Hinge Health to deliver personalized, evidence-based care solutions.

Hinge Health completed its Initial Public Offering (IPO) on May 21, 2025, with its shares commencing trading on the New York Stock Exchange (NYSE) on May 22, 2025, under the ticker symbol "HNGE".

This IPO represented a pivotal moment for the digital health industry, as Hinge Health became the first digital health company to enter the public market in 2025, effectively concluding a notable period of inactivity for digital health IPOs that had persisted since 2021. This market debut was closely observed by industry analysts and investors, who viewed it as a potential indicator for renewed investor interest in the digital health sector. The successful and positive reception of Hinge Health's IPO suggests that it could serve as a positive catalyst, potentially encouraging other digital health companies to pursue public listings and drawing additional capital into the sector. Conversely, a less favorable performance might have reinforced existing investor skepticism. Hinge Health's initial success, therefore, points to a renewed, albeit cautious, investor confidence in the viability of public market exits for digital health enterprises.

IPO Performance and Initial Share Price Trajectory

Hinge Health officially priced its initial public offering at $32.00 per share on May 21, 2025. The offering encompassed a total of 13,666,000 shares of its Class A common stock, with Hinge Health selling 8,522,528 shares and various selling stockholders contributing 5,143,472 shares. The IPO successfully raised $437 million, reflecting an implied valuation of $2.6 billion at the time of listing.

Since its market debut, Hinge Health's stock (HNGE) has demonstrated a significant upward trend. As of August 4, 2025, the stock was trading at $48.22 per share. This represents an increase of approximately 50.69% from its initial IPO price of $32.00. The user query noted a 56% increase, which aligns with the strong positive market sentiment and overall performance, acknowledging that daily market fluctuations can occur. Notably, prior to the release of its Q2 2025 earnings report on August 5, 2025, the shares had already appreciated by approximately 52% from their IPO price. Following the Q2 earnings announcement, the stock experienced a further surge of nearly 18% in after-hours trading, further cementing its impressive post-IPO performance. The 52-week high for HNGE stands at $52.16, while its 52-week low is $32.00, which corresponds to its IPO price.

The rapid and substantial appreciation of Hinge Health's stock post-IPO suggests that the market's perceived value of the company was considerably higher than its initial offering valuation. This strong initial market reaction and sustained increase indicate that investors either believed the company was undervalued at its IPO price, or that there was significant pent-up demand for a high-quality digital health offering in the public market after a period of limited IPO activity. This outcome reflects robust investor confidence in Hinge Health's business model and its future growth prospects. It is plausible that Hinge Health and its underwriters adopted a conservative pricing strategy for the IPO.

A lower initial price can help ensure a successful debut, generate positive momentum, and reward early investors, thereby fostering strong market sentiment and potentially facilitating future capital raises. This approach prioritises a successful and positive market entry over maximising immediate IPO proceeds, aiming to establish Hinge Health as a stable and attractive investment, a crucial factor for a newly public company operating in a sector where investor sentiment can be volatile.

Hinge Health IPO Details and Stock Performance Summary

Metric	Value
IPO Date	May 21, 2025
IPO Price per Share	$32.00
Shares Offered	13,666,000
Funds Raised at IPO	$437M
Implied IPO Valuation	$2.6B
Current Stock Price (Aug 4, 2025)	$48.22
% Change from IPO Price	~50.69% (based on $48.22 vs $32.00)
52-Week High	$52.16
52-Week Low	$32.00

Q2 2025 Financial Performance: A Deep Dive

Hinge Health delivered exceptional financial results in its first public quarterly report for Q2 2025. The company reported revenue of $139.1 million, marking a robust 55% year-over-year increase compared to $89.8 million in Q2 2024. This performance significantly outpaced Wall Street analysts' consensus expectations, which had projected revenue of $125 million. The strong revenue growth was primarily fuelled by an increase in eligible lives from both new and existing clients, coupled with better-than-expected enrollment yields. These factors collectively led to an increase in members and billings. Furthermore, the Last Twelve Months (LTM) calculated billings, a key forward indicator for future revenue, also surged by 55% to $568.4 million from $367.8 million in Q2 2024. The consistent growth in LTM billings provides a high degree of confidence in Hinge Health's future revenue trajectory, indicating successful client acquisition and retention, which are crucial for a recurring revenue model. This metric assures investors that the reported revenue growth is sustainable and not a one-off event.

The company demonstrated strong operational efficiency, achieving a non-GAAP gross margin of 83% in Q2 2025, an improvement from 77% in Q2 2024. This efficiency translated into a non-GAAP income from operations of $26.1 million, representing a substantial turnaround from a non-GAAP loss of $14.4 million in Q2 2024, and significantly exceeding the Street's target of $4 million. However, it is important to note that Hinge Health reported a substantial GAAP net loss of $576 million (or $13.10 per share) for Q2 2025, compared to a loss of $13 million in Q2 2024.

This significant GAAP loss was predominantly due to a $591.0 million stock-based compensation expense directly related to the IPO. This divergence highlights that the company's underlying operational performance and cash-generating ability are robust and profitable, distinct from the accounting impact of its IPO compensation structure. For investors, focusing on non-GAAP metrics and free cash flow provides a more accurate picture of the company's core business health and operational efficiency, preventing misinterpretation of the large reported GAAP loss as a sign of fundamental weakness.

The CEO's remarks about "reducing human care team hours associated with traditional physical therapy by approximately 95% through automation" and achieving "meaningful efficiency gains across the company from our AI initiatives" directly connect Hinge Health's technology investment to its improved non-GAAP gross margins and operational leverage. The significant increase in client numbers (32% year-over-year) alongside these efficiencies suggests that Hinge Health's model allows for substantial growth without a proportional increase in variable costs associated with human intervention. This demonstrates that Hinge Health's AI-powered platform is not merely a product feature but a fundamental enabler of its scalable business model and path to profitability. This operational efficiency is a key attractive feature for investors, showcasing how digital health solutions can deliver care more cost-effectively and at a larger scale than traditional models, aligning with broader healthcare trends towards automation and value.

Hinge Health also demonstrated strong cash generation, reporting $32.6 million in free cash flow for Q2 2025.This figure includes an adjustment of $14.2 million for employer taxes related to stock-based compensation at IPO. This represents a notable increase from $14.0 million in free cash flow during Q2 2024. The company concluded the quarter with a healthy cash, cash equivalents, marketable securities, and restricted cash balance of $415.1 million as of June 30, 2025, and notably, no debt.

The company's client base expanded significantly, with the number of clients increasing by 32% year-over-year to 2,359 in Q2 2025, up from 1,785 clients in Q2 2024. This growth in client acquisition, combined with increased eligible lives and enrolment yields, underscores the accelerating market demand for Hinge Health's digital MSK care solutions.

For the third quarter of 2025, Hinge Health projects revenue to be between $141 million and $143 million, reflecting a year-over-year growth of 41% at the midpoint. Non-GAAP income from operations is anticipated to be between $17 million and $21 million. For the full fiscal year 2025, the company expects revenue to range from $548 million to $552 million, representing 41% year-over-year growth at the midpoint. Non-GAAP income from operations for the full year is projected to be between $77 million and $83 million. Analysts observed that this full-year guidance came in well above Street estimates across all key metrics.

Hinge Health Key Financial Highlights (Q2 2025 vs Q2 2024 & FY 2025 Guidance)

Metric	Q2 2025 Actual	Q2 2024 Actual	FY 2025 Guidance (Midpoint)	Q2 2025 Analyst Expectations
Revenue	$139.1M	$89.8M	$550M	$125M
GAAP Gross Margin	70%	74%	N/A	N/A
Non-GAAP Gross Margin	83%	77%	N/A	N/A
GAAP Loss from Operations	($580.7M)	($17.6M)	N/A	N/A
Non-GAAP Income/(Loss) from Operations	$26.1M	($14.4M)	$80M	$4M
Net Loss	($575.7M)	($12.9M)	N/A	N/A
Free Cash Flow	$32.6M	$14.0M	N/A	N/A
Cash & Equivalents (as of June 30)	$415.1M	N/A	N/A	N/A
LTM Calculated Billings	$568.4M	$367.8M	N/A	N/A
Number of Clients	2,359	1,785	N/A	N/A

Strategic Initiatives and Business Expansion

Hinge Health's core offering is built upon its AI-powered digital exercise therapy program, specifically tailored for musculoskeletal (MSK) care. This platform seamlessly integrates advanced technology, including precision motion tracking (branded as "TrueMotion") and a wearable device for electrical nerve stimulation, with the expertise of its in-house clinicians. A significant aspect of the company's value proposition lies in its capacity to automate substantial portions of healthcare delivery, which has reportedly reduced human care team hours by approximately 95% compared to traditional physical therapy models.

This automation aims to enhance member outcomes and satisfaction while simultaneously reducing costs for clients.Recent product enhancements include a wider array of exercises and an innovative "Smart Skeleton" feature designed for improved 3D visualisations.

A pivotal strategic development following the IPO was the announcement and launch of HingeSelect on June 17, 2025. HingeSelect is positioned as a high-performance provider network that integrates Hinge Health's digital platform with access to a carefully selected network of in-person care providers, including local physical therapists, imaging centres, and physicians. The strategic objective is to create a "unified care experience," where Hinge Health's technology and in-house orthopaedic physicians efficiently triage and guide members to the most appropriate evidence-based treatment, whether delivered digitally or in-person.

This initiative also promises significant cost savings for employers and health plans, with in-person care being available at up to 50% below PPO rates and reduced member cost-sharing.This move signifies a strategic evolution towards a hybrid care model, acknowledging the practical realities and complexities of comprehensive healthcare delivery. By seamlessly integrating in-person services, Hinge Health broadens its appeal to a wider patient demographic and potentially enhances overall clinical outcomes, thereby strengthening its value proposition to employers and health plans seeking holistic and integrated solutions.

This also positions them more competitively against both purely digital and traditional in-person care providers. While a limited pilot is scheduled for late 2025 with a broader launch planned for 2026, a meaningful revenue contribution from HingeSelect is not anticipated until 2027. The design of HingeSelect, which offers in-person care at "up to 50% below PPO rates" and "reduces costs for employers" , is further supported by a medical claims analysis indicating an "average $2,343 savings per member per year" and a "2.4x return on investment (ROI) for fully insured health plan members". This demonstrates that Hinge Health is strategically positioning itself as a significant cost-reduction solution for its clients (employers and health plans). This strong financial benefit, alongside demonstrated clinical outcomes, makes their offering highly attractive in a healthcare market increasingly driven by value-based care and cost containment. This dual value proposition (clinical effectiveness and cost savings) is a powerful differentiator that can drive sustained client adoption and revenue growth.

Hinge Health has actively pursued strategic collaborations to significantly expand its market reach and service offerings. These include a new partnership with Cigna Healthcare, announced on April 22, 2025, aimed at broadening access to MSK care. A collaboration with Amazon Health Services, announced on December 5, 2024, was designed to improve the discoverability of Hinge Health's programs for over 18 million people across all 50 states. Additionally, a partnership with Midi Health, announced on August 27, 2024, aims to facilitate holistic menopause care, integrating movement-based support into its MSK platform. The company currently boasts a robust network of over 50 partners, including all five of the largest national health plans by self-insured lives and the three largest Pharmacy Benefit Managers (PBMs) by market share.

Beyond its established MSK offerings, Hinge Health is in the early stages of expanding into new and potentially lucrative market segments. These include working with fully-insured health plans, Medicare Advantage, and other government insurance programs.This strategic diversification into broader payer markets signals a long-term strategy to tap into larger, more complex, and often more regulated healthcare segments. While these markets offer immense growth potential and revenue diversification, they also introduce new challenges related to different reimbursement structures, regulatory compliance, and longer sales cycles compared to the employer market. Successful penetration here would significantly reduce revenue concentration risk and enhance the company's overall market footprint and stability.

Industry Landscape: Digital Health Trends and Regulatory Environment

The digital health sector is currently experiencing a rapid and profound transformation, driven by technological advancements and an increasing need for efficiency, accessibility, and personalised care.

Key overarching trends shaping the healthcare landscape in 2025 include the accelerated adoption of artificial intelligence (AI) and machine learning (ML), the expansion of digital healthcare services (including virtual and augmented reality applications), and a heightened focus on robust cybersecurity measures to protect sensitive patient data. AI and ML, in particular, are at the forefront of this revolution, enabling more accurate diagnoses, tailoring personalised treatment plans, and streamlining operational efficiencies across the healthcare continuum. Emerging solutions like ambient listening, AI-driven automation, and advanced remote patient monitoring are also gaining significant traction, addressing critical issues such as workforce shortages and boosting overall operational effectiveness.

AI agents are recognised for their "transformative potential to accelerate the evolution of healthcare by augmenting decision-making, personalising care, and automating repetitive tasks". These intelligent systems can analyse vast datasets, including medical histories, imaging, and genetic profiles, to provide clinicians with real-time, evidence-based insights, leading to faster and more accurate diagnoses and tailored treatments.Beyond clinical applications, AI is also optimising healthcare operations by automating administrative tasks like scheduling and billing, thereby reducing human error and freeing up clinical staff.

Hinge Health's strong emphasis on its "AI-powered platform" and reported "AI efficiencies" directly aligns with these dominant industry trends, positioning the company as a leader in leveraging cutting-edge technology for healthcare delivery. However, the rapid pace of technological innovation in AI within healthcare is outpacing the development of comprehensive regulatory frameworks. While Hinge Health's AI focus is a competitive strength, the lack of definitive, stable regulatory guidance for AI-enabled medical devices and the evidence required for their market clearance and reimbursement could introduce significant uncertainty, potential delays in product development, and unforeseen compliance costs.

This regulatory risk could impact the speed and scale of Hinge Health's innovation and market penetration.

The reimbursement landscape for digital therapeutics (DTx) remains a complex and evolving domain. While new reimbursement codes for digital therapeutics, Remote Therapeutic Monitoring (RTM), and AI-driven services became effective on January 1, 2025, early adoption is anticipated to be slow, and investors are keenly observing signs of meaningful traction.

Digital therapeutics companies are currently encountering "low and inconsistent Medicare payments" for their software, particularly for mental health conditions, which has prompted calls for the Centres for Medicare & Medicaid Services (CMS) to revise its approach to digital therapeutics reimbursement in the upcoming 2026 physician fee schedule. This implies that Hinge Health's ability to secure favorable and consistent reimbursement, particularly from government payers, will be a critical factor for its long-term growth and diversification strategy. It underscores the ongoing need for robust policy advocacy and adaptive business models within the digital health sector.

Analysts have consistently highlighted "ongoing risks tied to revenue concentration, suggesting a reliance on a limited group of large client contracts and uncertainties around evolving reimbursement models for digital therapeutics".They emphasise that Hinge Health's sustained growth trajectory will largely depend on its ability to successfully diversify its revenue streams and adeptly navigate these dynamic policy changes.

The company is demonstrably aware of and actively working to mitigate the revenue concentration risk. While securing large contracts provides significant scale, it also creates dependence. The strategic diversification into broader payer markets (health plans, government programs) is a direct, proactive response to this risk. The success of these diversification efforts will be crucial for long-term stability, reducing vulnerability to contract losses or renegotiations, and ensuring more resilient revenue streams. Furthermore, the CMS Final Rule 2025 introduces specific changes for physical therapy practices, including a 3.4% decrease in conversion factors for the Medicare Physician Fee Schedule, which could present headwinds, even as it offers new opportunities through caregiver training codes and expanded RTM services.

Analyst Sentiment and Future Outlook

Following its robust Q2 2025 earnings report, Hinge Health received largely positive updates to its analyst ratings and price targets. On August 6, 2025, Morgan Stanley maintained its "Overweight" rating and increased its price target from $46 to $57.

Stifel, on August 1, 2025, maintained a "Buy" rating, raising its target from $48 to $55. Other firms that initiated or maintained positive coverage in June and July 2025 include JMP Securities (Market Outperform, $58), Keybanc (Overweight, $60), Barclays (Overweight, $51), Piper Sandler (Overweight, $41), Truist Securities (Buy, $48), Raymond James (Outperform, $45), BofA Securities (Buy, $42), RBC Capital (Outperform, $45), William Blair (Outperform), and Needham (Buy, $47).

The range of these price targets indicates varying degrees of optimism but a general consensus of a positive outlook for the stock.

Analysts forecast Hinge Health to achieve significant earnings growth, with Earnings Per Share (EPS) expected to grow by 109.6% per annum and overall earnings by 98.9% per annum.The company is projected to become profitable within the next three years, a growth rate considered faster than the prevailing savings rate and above average market growth. In terms of revenue, analysts forecast a growth of 15.9% per annum.While this is a healthy growth rate, it is noted as being slower than the typical 20% per year benchmark for "high growth revenue".

This significant disparity between high earnings growth and more moderate revenue growth suggests that the company's path to profitability is heavily reliant on its ability to achieve substantial cost efficiencies and operational leverage, as demonstrated by its strong non-GAAP operating income in Q2 and its AI-driven efficiency gains.This implies that profitability isn't solely driven by top-line expansion. For investors, this indicates that Hinge Health's investment thesis is strongly tied to its operational discipline and its capacity to scale efficiently, rather than just aggressive market share capture. While revenue growth is important for market leadership, the impressive earnings growth forecast signals a strong focus on margin expansion and achieving sustainable profitability, a key signal for public market investors seeking mature growth companies.

Furthermore, the forecast Return on Equity (ROE) in three years is projected at 7.9%, which is considered low when compared to the industry average of 10.9%.ROE is a measure of how efficiently a company is generating profits from the equity invested by its shareholders. A relatively lower forecast ROE, even with high earnings growth, could subtly suggest that the company might require significant capital investment to sustain its projected growth, or that its capital efficiency might not be as strong as its industry peers in the long term. This is a nuanced long-term concern that warrants monitoring, as it could impact the overall returns to shareholders over an extended period, even if the short-term earnings picture is positive. It prompts questions about capital allocation and asset utilisation.

Despite the positive sentiment and strong financial performance, analysts continue to highlight key risks that warrant investor attention. These include potential revenue concentration, implying a reliance on a limited number of large client contracts, and ongoing uncertainties surrounding the evolving reimbursement models for digital therapeutics. While the Q2 report demonstrated strong operational execution, analysts emphasize the importance of monitoring Hinge Health's ability to achieve greater revenue stability and adapt to changes in payment models in the upcoming quarters.

Selected Analyst Ratings and Price Targets

Date	Analyst Firm	Previous Price Target	Current Price Target	Previous Rating	Current Rating
08/06/2025	Morgan Stanley	$46	$57	Maintains	Overweight
08/01/2025	Stifel	$48	$55	Maintains	Buy
07/14/2025	JMP Securities	N/A	$58	N/A	Market Outperform
07/14/2025	Keybanc	$45	$60	Maintains	Overweight
07/14/2025	Barclays	$43	$51	Maintains	Overweight
06/16/2025	Stifel	N/A	$48	N/A	Buy
06/16/2025	Piper Sandler	N/A	$41	N/A	Overweight
06/16/2025	Truist Securities	N/A	$48	N/A	Buy
06/16/2025	Raymond James	N/A	$45	N/A	Outperform
06/16/2025	Morgan Stanley	N/A	$46	N/A	Overweight
06/16/2025	B of A Securities	N/A	$42	N/A	Buy
06/16/2025	RBC Capital	N/A	$45	N/A	Outperform
06/16/2025	William Blair	N/A	N/A	N/A	Outperform
06/16/2025	Barclays	N/A	$43	N/A	Overweight
06/16/2025	Canaccord Genuity	N/A	$52	N/A	Buy
06/16/2025	Needham	N/A	$47	N/A	Buy

Final Thoughts

(The information contained in this blog post is not intended to constitute and should not be construed as, investment advice.)

Hinge Health's impressive approximately 56% surge in share price since its May 2025 IPO is a clear indicator of its compelling value proposition within the digital musculoskeletal care market and its strong operational execution. The exceptional Q2 2025 financial results, marked by significant revenue growth, robust non-GAAP operating income, and positive free cash flow, have evidently resonated with investors. These results validate the company's business model and its demonstrated ability to scale efficiently, largely driven by its AI-powered solutions.

Hinge Health has strategically positioned itself as a formidable leader in the digital health landscape. Its proactive expansion into a hybrid care model through HingeSelect, combined with its extensive network of partnerships with major national health plans and Pharmacy Benefit Managers (PBMs), provides a strong competitive advantage.

The company's unwavering focus on delivering evidence-based care, generating substantial cost savings for its clients, and continuous innovation in AI-powered therapy creates a significant and defensible competitive moat. By addressing the large and growing market for MSK care, which consistently ranks as a top healthcare expenditure for employers, Hinge Health is poised for continued relevance and growth.

Growth Drivers: Key drivers for future growth include sustained client acquisition and improved enrollment yields, strategic expansion into new market segments such as fully-insured health plans and Medicare Advantage, the anticipated full-scale launch of HingeSelect in 2026, and ongoing enhancements in AI-driven operational efficiencies. The broader macro trend of digital transformation in healthcare, particularly the increasing adoption of AI and machine learning, provides a highly favorable environment for Hinge Health's continued expansion.

Potential Headwinds: Despite the positive outlook, several challenges warrant careful monitoring. These include the need to effectively manage and mitigate identified revenue concentration by successfully diversifying its client base. Navigating the complex, evolving, and often inconsistent reimbursement landscape for digital therapeutics, particularly with government payers, will be crucial. Adapting to potential changes in regulatory guidance for AI-enabled medical devices and the intensifying competition within the digital therapeutics market also represent significant headwinds.

Nelson Advisors > Healthcare Technology M&A

Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide #Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech